ArticleArthritis and rheumatism2012
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice.
Article in Arthritis and rheumatism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Dual BAFF and APRIL inhibition with TACI-Fc depletes IgA plasma cells and ameliorates lupus nephritis.iScience · 2026Article
- Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study.Clinical rheumatology · 2025Observational
- T cell Dissimilarities in B Cell Activating Factor-Deficient Versus B Cell Activating Factor Receptor 3-Deficient Systemic Lupus Erythematosus-Prone NZM 2328 Mice as Contributors to Their Divergent Clinical Outcomes.ACR open rheumatology · 2024Article
- The circadian clock gene BMAL1 modulates autoimmunity features in lupus.Frontiers in immunology · 2024Article
- Inhibition of B cell activation followingJournal of translational autoimmunity · 2021Article
- Development of Murine Systemic Lupus Erythematosus in the Absence of BAFF.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- BAFF inhibition in SLE-Is tolerance restored?Immunological reviews · 2019Review
- Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice.Lupus science & medicine · 2019Article
- BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.Nature communications · 2018Article
- Delayed onset of autoreactive antibody production and M2-skewed macrophages contribute to improved survival of TACI deficient MRL-Fas/Lpr mouse.Scientific reports · 2018Article
- A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.European journal of immunology · 2017Article
- Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.Rheumatology (Oxford, England) · 2017Review
- Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.Drug design, development and therapy · 2017Review
- Profile of atacicept and its potential in the treatment of systemic lupus erythematosus.Drug design, development and therapy · 2015Review
- Effect of TACI signaling on humoral immunity and autoimmune diseases.Journal of immunology research · 2015Review
- APRIL mediates peritoneal B-1 cell homeostasis.Immunology letters · 2014Article
- The BAFF/APRIL system in SLE pathogenesis.Nature reviews. Rheumatology · 2014Review
- Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Future prospects in biologic therapy for systemic lupus erythematosus.Nature reviews. Rheumatology · 2013Review
- Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.Arthritis and rheumatism · 2013Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo determine the role of APRIL in the development of systemic lupus erythematosus (SLE) in mice.
methodsWild-type (WT) NZM 2328, NZM. April(-/-) , NZM.Baff(-/-) , and NZM.Baff(-/-) .April(-/-) mice were evaluated for lymphocyte phenotype by flow cytometry, for serum total IgG and IgG autoantibody levels by enzyme-linked immunosorbent assay, for glomerular deposition of IgG and C3 by immunofluorescence, for renal changes by histopathology, and for clinical disease by laboratory assessment (severe proteinuria).
resultsIn comparison to WT mice, NZM.April(-/-) mice harbored increased spleen B cells, T cells, and plasma cells (PCs), increased serum levels of IgG antichromatin antibodies, and decreased numbers of bone marrow (BM) PCs. Glomerular deposition of IgG and C3 was similar in NZM.April(-/-) mice and WT mice, renal changes on histopathology tended to be more severe in NZM.April(-/-) mice than in WT mice, and development of clinical disease was identical in NZM.April(-/-) mice and WT mice. BM (but not spleen) PCs and serum IgG antichromatin and anti-double-stranded DNA antibody levels were lower in NZM.Baff(-/-) .April(-/-) mice than in NZM.Baff(-/-) mice, whereas renal immunopathology in each cohort was equally mild.
conclusionAPRIL is dispensable for the development of full-blown SLE in NZM mice. Moreover, the elimination of both APRIL and BAFF had no discernible effect on the development of renal immunopathology or clinical disease beyond that of elimination of BAFF alone. The reduction in BM PCs in hosts doubly deficient in APRIL and BAFF beyond that in hosts deficient only in BAFF raises concern that combined antagonism of APRIL and BAFF may lead to greater immunosuppression without a concomitant increase in therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.